· 19hNovo Nordisk's obesity drug Wegovy goes on sale in China
Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.A Novo Nordisk spokesperson confirmed to AFP on Tuesday that the drug was "now available in China" for the treatment of adults with obesity and those overweight with at least one weight-related comorbidity.
13hon MSNOpinion
The COVID pandemic set in motion trends with alcohol use that have persisted. Disruptions in work, school and lifestyle have ...
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.
MedPage Today on MSN1d
Over 50% of U.S. Adults Qualify for Ozempic, WegovyMore than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.
Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...
For years, Miriam Schulman of Highland Park, New Jersey, struggled with what she called ‘food noise.’ “You’re always thinking ...
The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback